Certified Hospice and Palliative Assistant (CHPNA) Practice Test 2026 - Free CHPNA Exam Practice Questions and Preparation Guide

During the equianalgesic conversion process, breakthrough doses should be included in the total amount of the current drug to ensure an accurate assessment of the patient's pain management needs. This inclusion acknowledges the pain that is not adequately controlled by the current regimen and allows for a more precise calculation when converting to a different medication or dosage regimen.

Breakthrough doses reflect the additional medication taken by the patient to manage pain that exceeds the baseline coverage, and failing to account for these doses could lead to under-treatment of pain. By incorporating them into the calculation, practitioners can provide a more effective and tailored pain management strategy for the patient, ensuring that both the regular and breakthrough doses contribute to the overall opioid requirement and avoiding potential gaps in analgesia.